Sitemap
- Chapters
- 1. Gastro–Intestinal System
- Dyspepsia Management Guidelines ~ Summary
- 1.1.1 Antacids and simeticone
- 1.1.2 Compound alginates and proprietary indigestion preparation
- 1.2 Antispasmodics and other drugs altering gut motility
- 1.3.1 H2–receptor antagonists
- 1.3.3 Chelates and complexes
- 1.3.4 Prostaglandin analogues
- 1.3.5 Proton Pump Inhibitors (PPIs)
- 1.4.2 Antimotility drugs
- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids
- 1.5.3 Drugs affecting the immune response
- 1.6.1 Bulk–forming laxatives
- 1.6.2 Stimulant laxatives
- 1.6.3 Faecal softeners
- 1.6.4 Osmotic laxatives
- Guidelines for the management of constipation in adults
- Clinical Guideline: Constipation in Children
- 1.6.5 Bowel cleansing solutions
- 1.6.6 Peripheral opioid–receptor antagonists
- 1.6.7 5HT4 receptor agonists
- 1.7.1 Soothing haemorrhoidal preparations
- 1.7.2 Compound haemorrhoidal preparations with corticosteroids
- 1.7.3 Rectal sclerosants
- 1.8 Stoma care
- 1.9.1 Drugs acting on the gall bladder
- 1.9.2 Bile acid sequestrants
- 1.9.4 Pancreatin
- 2. Cardiovascular System
- 2.1.1 Cardiac glycosides
- 2.1.2 Phosphodiesterase inhibitors
- 2.2.1 Thiazide and related diuretics
- 2.2.2 Loop diuretics
- 2.2.3 Potassium–sparing diuretics
- 2.2.4 Potassium–sparing diuretics with other diuretics
- 2.2.5 Osmotic diuretics
- 2.3.2 Drugs for arrhythmias
- 2.4 Beta–adrenoceptor blocking drugs
- 2.5.1 Vasodilator antihypertensive drugs
- 2.5.2 Centrally acting antihypertensive drugs
- 2.5.4 Alpha–adrenoreceptor blocking drugs
- 2.5.5 Drugs affecting the renin–angiotensin system
- 2.6.1 Nitrates
- 2.6.2 Calcium–channel blockers
- 2.6.3 Other antianginal drugs
- 2.6.4 Peripheral and cerebral vasodilators
- 2.7.1 Inotropic sympathomimetics
- 2.7.2 Vasoconstrictor sympathomimetics
- 2.7.3 Cardiopulmonary resuscitation
- 2.8.1 Parenteral anticoagulants
- 2.8.2 Oral anticoagulants
- 2.8.3 Protamine sulphate
- 2.9 Antiplatelet drugs
- 2.10.2 Fibrinolytic drugs
- 2.11 Antifibrinolytic drugs and haemostatics
- 2.12 Lipid–lowering drugs
- 2.13 Local sclerosants
- 3. Respiratory System
- Guidance on inhaler devices and Nebulised therapy
- COPD Self–Management – Patients at risk of an exacerbation
- 3.1.1 Adrenoceptor agonists
- 3.1.2 Anitmuscarinic bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound bronchodilator preparations
- 3.1.5 Peak flow meters, inhaler devices and nebulisers
- Corticosteroid licensed age indications and beclometasone diproprionate equivalence
- 3.2 Corticosteroids
- 3.3.2 Leokotriene receptor antagonist
- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic emergencies
- 3.5.1 Respiratory stimulents
- 3.5.2 Pulmonary surfactants
- 3.6 Oxygen
- 3.7 Mucolytics
- 3.8 Aromatic inhalations
- 3.9.1 Cough suppressants
- 3.9.2 Expectorant & demulcent cough preparations
- 3.10 Systemic nasal decongestants
- 4. Central Nervous System
- 4.1.1 Hypnotics
- 4.1.2 Anxiolytics
- 4.1.3 Barbiturates
- 4.2.1 Antipsychotic drugs
- 4.2.2 Antipsychotic depot injections
- 4.2.3 Antimanic drugs
- 4.3.1 Tricyclic (TCA) and related antidepressant drug
- 4.3.2 Monoamine–oxidase inhibitors
- 4.3.3 Selective serotonin re–uptake inhibitors (SSRIs)
- 4.3.4 Other antidepressant drugs
- 4.4 Central nervous system stimulants
- 4.5.1 Drugs used in the treatment of obesity
- 4.5.2 Centrally acting appetite suppressants
- 4.6 Drugs used in nausea and vertigo
- 4.7.1 Non opioid analgesics and compound analgesic preparations
- 4.7.2 Opioid analgesics
- 4.7.3 Neuropathic pain
- 4.7.4 Antimigraine drugs
- 4.8.1 Control of epilepsy
- 4.8.2 Status epilepticus
- 4.8.3 Febrile convulsions
- 4.9.1 Dopaminergic drugs used in Parkinson’s Disease
- 4.9.2 Antimuscarinic drugs used in parkinsonism
- 4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders
- 4.10.1 Alcohol dependence
- 4.10.2 Nicotine dependence
- 4.10.3 Opioid dependence
- 4.11 Drugs for dementia
- 5. Infections
- 5.1.1 Penicillins
- 5.1.2 Cephalosporins and other beta–lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other antibacterials
- 5.1.8 Sulphonamides and trimethoprim
- 5.1.9 Antituberculosis drugs
- 5.1.10 Antileprotic drugs
- 5.1.11 Metronidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary–tract infections
- 5.2 Antifungal drugs
- 5.3.1 HIV infection
- 5.3.2 Herpes virus infections
- 5.3.3 Viral hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory syncytial virus (RSV)
- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.4 Antigardial drugs
- 5.4.8 Drugs for pneumocystis pneumonia
- 5.5.1 Drugs for threadworms
- 5.5.2 Ascaricides
- 5.5.3 Drugs for tapeworm infections
- 5.5.4 Drugs for hookworms
- 5.5.5 Schistosomicides
- 5.5.6 Filaricides
- 5.5.7 Drugs for cutaneous larva migrans
- 5.5.8 Drugs for strongyloidiasis
- Primary Care Antimicrobial Guidelines
- Plymouth Hospitals Antibiotic Treatment Guidelines
- 6. Endocrine System
- Joint Formulary – Summary of available insulins
- 6.1.1 Insulins
- 6.1.2 Antidiabetic drugs
- 6.1.4 Treatment of hypoglycaemia
- 6.1.6 Diagnostic and monitoring devices for diabetes mellitus
- 6.2.1 Thyroid Hormones
- 6.2.2 Antithyroid drugs
- 6.3.1 Replacement therapy (mineralocorticoid)
- 6.3.2 Glucocorticoid therapy
- 6.4.1 Female Sex hormones
- 6.4.2 Male sex hormones and antagonists
- 6.5.1 Hypothalamic and pituitary hormones and anti–oestrogens
- 6.5.2 Posterior pituitary hormones and antagonists
- 6.6.1 Calcitonin and parathyroid hormone
- 6.6.2 Bisphosphonates
- 6.7.1 Bromocriptine and other dopamine–receptor stimulants
- 6.7.2 Drugs affecting gonadotrophins
- 6.7.3 Metyrapone
- 7. Obstetrics, Gynaecology and Urinary–tract Disorders
- 7.1.1 Prostaglandins and oxytocics
- 7.1.2 Mifepristone
- 7.1.3 Myometrial relaxants
- 7.2.1 Preparations for vaginal atrophy
- 7.2.2 Anti–infective drugs
- 7.3 General Information
- 7.3.1 Combined oral contraceptives (COCs)
- 7.3.2 Progestogen–only contraceptives
- 7.3.3 Spermicidal contraceptives
- 7.3.4 Contraceptive devices
- 7.3.5 Emergency contraception
- 7.4.1 Drugs for urinary retention
- 7.4.2 Drugs for urinary frequency, enuresis and incontinence
- 7.4.3 Drugs used in urological pain
- 7.4.4 Bladder instillations and urological surgery
- 7.4.5 Drugs for erectile dysfunction
- 8. Malignant Disease and Immunossuppression
- General Information and contact details
- Side–effects of cytotoxic drugs
- Treatments for cytotoxic–induced side effects
- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines and other cytotoxic antibiotics
- 8.1.3 Antimetabolites
- 8.1.4 Vinca alkaloids and etoposide
- 8.1.5 Other antineoplastic drugs
- 8.2.1 Antiproliferative immunosuppressants
- 8.2.2 Corticosteroids and other immunosuppressants
- 8.2.3 Anti–lymphocyte monoclonal antibodies
- 8.2.4 Other immunomodulating drugs
- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
- 8.3.4 Hormone antagonists
- 9. Nutrition and Blood
- 9.1.1 Iron–deficiency anaemias
- 9.1.2 Drugs used in megaloblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias
- 9.1.4 Drugs used in platelet disorders
- 9.1.5 G6PD deficiency
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells
- 9.2.1 Oral preparations for fluid and electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid and electrolyte imbalance
- 9.3 Intravenous nutrition
- 9.4.1 Foods for special diets
- 9.4.2 Enteral nutrition
- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc
- 9.5.5 Selenium
- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations
- 9.7 Bitters and tonics
- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias
- 10. Musculoskeletal and Joint Diseases
- 10.1.1 Non–steroidal anti–inflammatory drugs
- 10.1.2 Corticosteroids
- 10.1.3 Drugs which suppress the rheumatic disease process
- 10.1.4 Gout and cytotoxic–induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases
- 10.2.1 Drugs which enhance neuromuscular transmission
- 10.2.2 Skeletal muscle relaxants
- 10.3.1 Enzymes
- 10.3.2 Rubefacients and other topical antirheumatics
- Other products
- 11. Eye
- 11.1 Administration of drugs to the eye
- 11.2 Control of microbial contamination
- 11.3 Anti–infective eye preparations
- 11.4 Corticosteroids and other anti–inflammatory preparations
- 11.5 Mydriatics and cycloplegics
- 11.6 Treatment of glaucoma
- 11.7 Local anaesthetics
- 11.8 Miscellaneous ophthalmic preparations
- 11.9 Contact lenses
- 12. Ear, Nose and Oropharynx
- 13. Skin
- 13.1.2 Suitable quantities for prescribing
- 13.1.3 Excipients and sensitisation
- 13.2.1 Emollients
- 13.2.2 Barrier preparations
- 13.3 Topical local anaesthetics and antipruritics
- 13.4 Topical corticosteroids
- 13.5.1 Preparations for eczema
- 13.5.2 Preparations for psoriasis
- 13.5.3 Drugs affecting the immune response
- 13.6.1 Topical preparations for acne
- 13.6.2 Oral preparations for acne
- 13.7 Preparations for warts and calluses
- 13.8.1 Sunscreen preparations
- 13.8.2 Camouflagers
- 13.9 Shampoos and other preparations for scalp and hair conditions
- 13.10.1 Antibacterial preparations
- 13.10.2 Antifungal preparations
- 13.10.3 Antiviral preparations
- 13.10.4 Parasiticidal preparations
- 13.10.5 Preparations for minor cuts and abrasions
- 13.11.1 Alcohols and saline
- 13.11.2 Chlorhexidine salts
- 13.11.4 Iodine
- 13.11.6 Oxidisers and dyes
- 13.12 Antiperspirants
- 13 Other products
- 14. Immunological Products and Vaccines
- 15. Anaesthesia
- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative and analgesic peri–operative drugs
- 15.1.5 Neuromuscular blocking drugs
- 15.1.6 Drugs for reversal of neuromuscular blockade
- 15.1.7 Antagonists for central respiratory depression
- 15.1.8 Drugs for malignant hyperthermia
- 15.2 Local anaesthesia
- 16. Palliative Care Guidelines
- Specialist Palliative Care Services – Contact details
- Treatment of chronic cancer pain
- Breakthrough Pain / Incident Pain
- Use of Opioids in Renal Failure
- Adjuvant Analgesia
- Anti–emetics
- Bowel Management / Constipation
- The Medical Management of Malignant Intestinal Obstruction in Palliative Care
- The Use of Steroids in Palliative Care
- Hypercalcaemia of Malignancy
- Confusion, Restlessness and Agitation
- Breathlessness
- Oral Candidiasis / Mouth Care
- The Syringe Driver
- Liverpool Care Pathway (LCP)
- Just in Case Bags
- 17 Wound Management
- Ideal dressing
- Wound Classification
- Guidelines for the management and care of colonised or infected wounds
- Wound cleansing – irrigation
- Antibacterial Preparations
- 17.1 (A8.1) Basic wound contact dressings
- 17.2 (A8.2) Advanced wound dressings
- 17.3 (A8.3) Antimicrobial dressings
- 17.4 (A8.4) Specialised dressings
- 17.6 (A8.6) Complex adjunct therapies
- Other wound management products
- 17.7 (A8.7) Wound care accessories
- 18. Dental Prescribing
- Alphabetical list of products
- Introduction & information
- Proton Pump Inhibitors (BNF 1.3.5
- Antihistamines (BNF 3.4.1)
- Aromatic inhalations (BNF 3.8)
- Hypnotics (BNF 4.1.1)
- Anxiolytics (BNF 4.1.2)
- Non–opioid Analgesics (BNF 4.7.1)
- Opioid analgesics (BNF 4.7.2)
- Neuropathic pain (BNF 4.7.3)
- Benzylpenicillin and phenoxymethylpenicillin (BNF 5.1.1.1)
- Broad–spectrum penicillins (BNF 5.1.1.3)
- Cephalosporins and other beta–lactams (BNF 5.1.2)
- Tetracyclines (BNF 5.1.3)
- Macrolides (BNF 5.1.5)
- Clindamycin (BNF 5.1 6)
- Metronidazole (BNF 5.1.11)
- Antifungal drugs (BNF 5.2)
- Herpes virus infections (BNF 5.3.2)
- Fluoride (BNF 9.5.3)
- Non–steroidal anti–inflammatory drugs (BNF 10.1.1)
- Topical nasal decongestants (BNF 12.2.2)
- Drugs for oral ulceration and inflammation (BNF 12.3.1)
- Oropharyngeal anti–infective drugs(BNF 12.3.2)
- Mouthwashes, gargles and dentifrices (BNF 12.3.4)
- Treatment of Dry Mouth (BNF 12.3.5)
- Topical corticosteroids (BNF 13.4)
- Antibacterial preparations (BNF 13.10.1)
- Anitviral preparations (BNF 13.10.3)
- 19. Miscellaneous Preparations
- 20. Shared Care Information
- Shared Care Information ~ Treatment of Alzheimer’s Disease
- Shared care information on the prescribing of Atomoxetine
- Shared care Information ~ Azathioprine, Rheumatology
- Shared care information on the prescribing of Azathioprine and Mercaptopurine
- Shared care Information ~ Ciclosporin, Rheumatology
- Shared care information on the prescribing of Ciclosporin
- Shared care information for the prescribing of cinacalcet
- Shared care Information ~ Cyclophosphamide, Rheumatology
- Shared care information on the prescribing of cyclophosphamide
- Shared care information for Erythropoietin and Darbepoetin
- Shared care information on the prescribing of enoxaparin
- Shared care information on the prescribing of Gonadorelin Analogues (Gnrh)
- Shared Care Information on the Prescribing of Grazax
- Shared Care Information on the Prescribing of Hydroxycarbamide
- Shared care Information ~ Hydroxychlorquine, Rheumatology
- Shared care information on the prescribing of Hydroxychloroquine
- Shared care Information ~ Leflunomide, Rheumatology
- Shared care information on the prescribing of Leflunomide
- Shared care information on the prescribing of Lithium (Priadel)
- Shared care Information ~ Methotrexate, Rheumatology
- Shared care information on the prescribing of oral Methotrexate
- Shared care information on the prescribing of Methylphenidate
- Shared care information on the prescribing of Mycophenolate Mofetil
- Shared care information on the prescribing of Mycophenolic Acid (Myfortic)
- Shared care Information ~ Penicillamine, Rheumatology
- Shared care information on the prescribing of Riluzole
- Shared care information on the prescribing of Sirolimus
- Shared care Information ~ Sodium Aurothiomalate, Rheumatology
- Shared care information on the prescribing of Somatropin (Growth Hormone) in adults
- Shared care information on the prescribing of somatostatin analogues – acromegaly in adults
- Shared care on prescribing of somatostatin analogues – gastrointestinal neuroendocrine tumours
- Shared care information on the prescribing of Sulfasalazine
- Shared care Information ~ Sulfasalazine, Rheumatology
- Shared care information on the prescribing of Tacrolimus
- Shared care information on the prescribing of TOBI (tobramycin)
- 21. Continence Formulary
- 1. Gastro–Intestinal System
- About the Formulary and Local Decisions
- Current Chapter Reviews
- General Prescribing Info
- Financial and clinical responsibility for prescribing non–formulary drugs
- Format of the Formulary
- Unlicensed Drugs
- Borderline foods and dietary products (ACBS)
- Selective List Scheme (SLS)
- Travelling or extended stays abroad
- Overseas visitors
- When not to prescribe generically
- Prescribing liquid medicines for children.
- Medical Exemption Certificates (Medex)
- GP System Formulary Downloads
- Useful Links
- Copyright Notice
- Accessibility
- Cookie Policy
- Sitemap
- Site by toucan
Please click on the links below for more information
-
BNF
-
NICE
-
Summary of product characteristics
